FOXO3 and breast cancer: Prolong treatment of breast cancer cells with AKT inhibitors (which inhibit AKT phosphorylation) induces dephosphorylation of FOXO3a, nuclear translocation, and destruction of its binding to SIRT6, resulting in FOXO3a acetylation and BRD4 recognition [64].